Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Hepatology. 2018 Jul 16;68(4):1347–1360. doi: 10.1002/hep.29914

Figure 1. Increased NET marker in human NASH.

Figure 1

(A) Patients with histopathologically proven NASH (n=46) have increased serum levels of MPO-DNA when compared with matched patients with normal liver histology (n=30). (B) MPO-DNA levels stratified by disease type (benign, primary malignant, metastatic). For any disease type, median MPO-DNA levels were higher when NASH was present in the background liver compared to a normal background liver.